Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline

Antimicrobial Agents and Chemotherapy
Laura HoneymanS B Levy

Abstract

A series of novel tetracycline derivatives were synthesized with the goal of creating new antibiotics that would be unaffected by the known tetracycline resistance mechanisms. New C-9-position derivatives of minocycline (the aminomethylcyclines [AMCs]) were tested for in vitro activity against Gram-positive strains containing known tetracycline resistance mechanisms of ribosomal protection (Tet M in Staphylococcus aureus, Enterococcus faecalis, and Streptococcus pneumoniae) and efflux (Tet K in S. aureus and Tet L in E. faecalis). A number of aminomethylcyclines with potent in vitro activity (MIC range of ≤0.06 to 2.0 μg/ml) were identified. These novel tetracyclines were more active against one or more of the resistant strains than the reference antibiotics tested (MIC range, 16 to 64 μg/ml). The AMC derivatives were active against bacteria resistant to tetracycline by both efflux and ribosomal protection mechanisms. This study identified the AMCs as a novel class of antibiotics evolved from tetracycline that exhibit potent activity in vitro against tetracycline-resistant Gram-positive bacteria, including pathogenic strains of methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE). One derivative, 9-...Continue Reading

References

Jan 5, 2002·Current Opinion in Pharmacology·I Chopra
Jul 19, 2003·The Journal of Organic Chemistry·Mark L NelsonStuart B Levy
Jun 28, 2005·Drugs·Ethan Rubinstein, David Vaughan
Jul 26, 2005·The Journal of Antimicrobial Chemotherapy·George A Pankey
Oct 29, 2009·Cellular and Molecular Life Sciences : CMLS·Maulik ThakerGerard D Wright
Dec 24, 2011·Annals of the New York Academy of Sciences·Mark L Nelson, Stuart B Levy
Sep 18, 2013·Antimicrobial Agents and Chemotherapy·Michael P DraperStuart B Levy
Dec 4, 2013·Antimicrobial Agents and Chemotherapy·A B MaconeS B Levy

❮ Previous
Next ❯

Citations

Oct 18, 2016·MedChemComm·Jed F Fisher, Shahriar Mobashery
Jun 30, 2016·The Journal of Antibiotics·Mark S ButlerMatthew A Cooper
Sep 20, 2016·MedChemComm·Jesse A JonesKirk E Hevener
Aug 20, 2016·Journal of Clinical Pharmacology·Evan TzanisEvan Loh
Aug 19, 2017·Natural Product Reports·Olga Genilloud
Jun 14, 2018·Expert Opinion on Drug Safety·Matteo BassettiElda Righi
Nov 22, 2017·Antimicrobial Agents and Chemotherapy·Jolene K BergStephen Villano
Feb 15, 2017·Antimicrobial Agents and Chemotherapy·Alexander J LepakDavid R Andes
Feb 23, 2017·Antimicrobial Agents and Chemotherapy·Judith SteenbergenJeremy R Hershfield
Oct 6, 2018·Pharmacotherapy·Katie E BarberKayla R Stover
Feb 7, 2019·The New England Journal of Medicine·William O'RiordanEvan Loh
Feb 7, 2019·The New England Journal of Medicine·Roman StetsEvan Loh
Apr 24, 2019·Pharmaceuticals·Fernando Durães, Emília Sousa
May 1, 2019·Antimicrobial Agents and Chemotherapy·Alexander J LepakDavid R Andes
Aug 2, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jason C Gallagher
Aug 21, 2019·Microorganisms·Despoina KoulentiUNKNOWN SotiriosTsiodras
Nov 28, 2019·Clinical Pharmacokinetics·Keith A RodvoldManjunath P Pai
Feb 26, 2020·Antimicrobial Agents and Chemotherapy·Jacques DuboisJean-François Martel
Apr 29, 2020·Antimicrobial Agents and Chemotherapy·Elizabeth A LakotaChristopher M Rubino
Dec 19, 2017·Current Opinion in Infectious Diseases·Philippe MontraversSebastien Tanaka
Apr 4, 2018·Expert Opinion on Investigational Drugs·Lindsay M Avery, David P Nicolau
Mar 29, 2019·The Annals of Pharmacotherapy·John A DoughertyKatherine C Shihadeh
Jan 24, 2020·Drugs·George G ZhanelJames A Karlowsky
May 16, 2020·Pathogens·Vladimir SavranskyJoshua Reece
Nov 18, 2019·Current Infectious Disease Reports·David A ButlerEric Wenzler
Mar 21, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard R Watkins, Stan Deresinski
Jan 28, 2021·Medicinal Research Reviews·Laiying ZhangYoufu Luo
Jan 22, 2021·Bioorganic & Medicinal Chemistry Letters·Qidi Kong, Yushe Yang
Oct 15, 2020·Nucleic Acids Research·Aurélien F A MoumbockStefan Günther
Jan 12, 2021·Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine·Alessandro Russo

❮ Previous
Next ❯

Software Mentioned

WinNonlin

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.